In preclinical studies, MEK inhibitors were also shown to reduce the lung metastasis of breast cancer and inhibit breast cancer stem cells, suggesting the clinical potential for patients with breast cancer whose tumors are MAPK dependent (Bartholomeusz et al., 2015). Here, MAP2K7 is linked to breast carcinoma.